Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | PDXK | O00764 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8571001 | 0.84 | TTR (0.33) | TTRKDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL28309412 | 0.78 | TTR (0.34) | TTRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1602573 | 0.76 | ALDH1A1 (0.43) | ALDH1A1HPGDHSD17B10MEN1CYP3A4 | |
| SCHEMBL24568238 | 0.76 | TTR (0.40) | TTRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31085043 | 0.75 | KEAP1 (0.33) | S1PR4KDM4EALDH1A1HPGDPDXK | |
| SCHEMBL21306836 | 0.75 | SHBG (0.38) | TTRS1PR4KDM4EALDH1A1HPGD | |
| SCHEMBL9973785 | 0.75 | CYP3A4 (0.36) | TTRS1PR4KDM4EALDH1A1HPGD | |
| SCHEMBL16517376 | 0.73 | KDM4E (0.36) | S1PR4KDM4EALDH1A1CYP1A2MAPT | |
| SCHEMBL411440 | 0.71 | BPTF (0.37) | S1PR4KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL5917844 | 0.71 | PDXK (0.33) | S1PR4KDM4EALDH1A1HPGDPDXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110753690-B | Pyridine derivatives | 豪夫迈·罗氏有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-3642200-B1 | PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-03 | — | — | EP | disclosed |
| EP-3642200-B1 | PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-03 | — | — | EP | disclosed |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | Janssen Biopharma, Inc. (US) | 2022-11-17 | — | — | US | disclosed |
| CN-114716426-A | Antiviral compounds | 詹森生物制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-105636936-B | Antiviral compounds | 詹森生物制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20220064178-A1 | PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220064178-A1 | PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-03-03 | — | — | US | disclosed |
| US-11117903-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117903-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-07-10 | — | — | US | disclosed |
| US-20030105089-A1 | Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003042210-A1 | AZABICYCLIC-PHENYL-FUSED-HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALPHA7 NACHR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003037896-A1 | N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-17 | — | — | US | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003022856-A1 | SUBSTITUTED 7-AZA[2.2.1] BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100858-A2 | QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | TPMT, PAICS, MALT1 | TTR 1693/4885S1PR4 1241/4885KDM4E 1516/4885 |
| US-20030105089-A1 | Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CHRNA7, CHRNA1, CHRNA6 | TTR 3236/4885S1PR4 1498/4885KDM4E 1290/4885 |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | NAT1, UGT1A1, SLC10A1 | TTR 2381/4885S1PR4 3871/4885KDM4E 3540/4885 |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | TTR 2792/4885S1PR4 3351/4885KDM4E 4297/4885 |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | TTR 4331/4885S1PR4 1646/4885KDM4E 3737/4885 |
| US-20220064178-A1 | PYRIDINE DERIVATIVES | NDUFS6, NDUFS3, CYP11B2 | TTR 3861/4885S1PR4 1166/4885KDM4E 1500/4885 |
| US-11117903-B2 | Pyridine derivatives | NDUFS6, NDUFS3, CYP11B2 | TTR 3861/4885S1PR4 1166/4885KDM4E 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.